• Consensus Rating: Hold
  • Consensus Price Target: $109.25
  • Forecasted Upside: 537.40 %
  • Number of Analysts: 7
  • Breakdown:
  • 2 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$17.14
▲ +0.36 (2.15%)

This chart shows the closing price for NVAX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Novavax Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVAX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVAX

Analyst Price Target is $109.25
▲ +537.40% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Novavax in the last 3 months. The average price target is $109.25, with a high forecast of $207.00 and a low forecast of $27.00. The average price target represents a 537.40% upside from the last price of $17.14.

This chart shows the closing price for NVAX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 7 polled investment analysts is to hold stock in Novavax. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 2 sell ratings
6/15/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
9/13/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
12/12/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
3/12/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 2 sell ratings
6/10/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 2 sell ratings
9/8/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 2 sell ratings
11/7/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 2 sell ratings
12/7/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/2/2022Jefferies Financial GroupInitiated CoverageHoldLow
11/10/2022B. RileyLower Target$83.00 ➝ $74.00Low
10/14/2022B. RileyLower TargetBuy$126.00 ➝ $83.00Low
10/13/2022CowenLower Target$55.00Low
9/22/2022JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$132.00 ➝ $27.00Low
8/15/2022CowenLower Target$110.00N/A
8/9/2022CowenLower Target$150.00 ➝ $110.00N/A
8/9/2022CowenLower TargetOutperform$150.00 ➝ $110.00N/A
7/22/2022B. RileyLower Target$181.00 ➝ $171.00Low
6/8/2022Cantor FitzgeraldBoost Target$146.00 ➝ $168.00High
6/3/2022CowenReiterated RatingBuy$150.00High
5/20/2022Bank of AmericaInitiated CoverageUnderperform$35.00High
5/11/2022B. RileyLower Target$203.00 ➝ $181.00High
4/26/2022B. RileyLower TargetBuy$250.00 ➝ $203.00High
3/3/2022HC WainwrightLower TargetBuy$294.00 ➝ $207.00High
3/2/2022B. RileyLower Target$265.00 ➝ $250.00High
2/23/2022B. RileyLower TargetBuy$315.00 ➝ $265.00High
2/22/2022Jefferies Financial GroupInitiated CoverageBuy$198.00Medium
2/14/2022Cantor FitzgeraldLower TargetOverweight$282.00 ➝ $174.00High
1/21/2022CowenInitiated CoverageOutperform$150.00Medium
1/4/2022B. RileyBoost Target$305.00 ➝ $315.00Medium
12/21/2021JPMorgan Chase & Co.Boost TargetNeutral$172.00 ➝ $209.00High
9/1/2021Chardan CapitalReiterated RatingNeutralN/A
6/15/2021Cantor FitzgeraldBoost TargetReduce ➝ Overweight$217.00 ➝ $272.00High
5/18/2021JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Neutral$285.00 ➝ $161.00Medium
5/12/2021B. RileyLower TargetBuy$365.00 ➝ $286.00High
5/12/2021Cantor FitzgeraldLower TargetOverweight$338.00 ➝ $217.00High
5/12/2021HC WainwrightLower TargetBuy$317.00 ➝ $294.00High
5/12/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$285.00 ➝ $161.00High
5/11/2021Jefferies Financial GroupLower TargetPositive ➝ Buy$310.00 ➝ $235.00Medium
3/12/2021HC WainwrightBoost TargetBuy$207.00 ➝ $317.00High
2/5/2021Cantor FitzgeraldBoost TargetOverweight$248.00 ➝ $338.00Low
2/1/2021B. RileyBoost TargetBuy$223.00 ➝ $334.00Low
1/29/2021Cantor FitzgeraldBoost TargetOverweight$211.00 ➝ $248.00High
12/14/2020Jefferies Financial GroupInitiated CoverageBuy$200.00Low
11/17/2020HC WainwrightLower TargetBuy$290.00 ➝ $207.00Medium
10/22/2020B. RileyLower Target$223.00 ➝ $257.00Low
8/17/2020B. RileyReiterated RatingBuy$257.00High
8/5/2020LADENBURG THALM/SH SHDowngradeNeutral ➝ Sell$105.00High
8/5/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$105.00 ➝ $275.00High
7/16/2020B. RileyBoost TargetBuy$106.00 ➝ $155.00Low
7/16/2020HC WainwrightBoost TargetBuy$101.00 ➝ $132.00High
7/8/2020LADENBURG THALM/SH SHReiterated RatingBuy ➝ Neutral$50.00 ➝ $105.00High
7/7/2020Cantor FitzgeraldBoost Target$88.00 ➝ $148.00Medium
6/29/2020B. RileyBoost TargetBuy$74.00 ➝ $106.00High
6/29/2020HC WainwrightBoost TargetBuy$50.00 ➝ $101.00High
6/19/2020Cantor FitzgeraldBoost TargetOverweight$45.00 ➝ $88.00High
6/5/2020B. RileyBoost Target$61.00 ➝ $74.00Low
6/5/2020JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$46.00High
6/3/2020B. RileyReiterated RatingBuy$61.00Low
5/26/2020B. RileyReiterated RatingBuy$53.00 ➝ $61.00High
5/18/2020B. RileyBoost TargetBuy$43.00 ➝ $53.00High
5/14/2020LADENBURG THALM/SH SHBoost Target$38.00 ➝ $50.00Low
5/12/2020Cantor FitzgeraldBoost TargetOverweight$23.00 ➝ $45.00High
5/12/2020OppenheimerBoost TargetOutperform$19.00 ➝ $38.50High
5/12/2020B. RileyBoost TargetBuy$29.00 ➝ $43.00High
5/12/2020HC WainwrightReiterated RatingBuy$33.00 ➝ $50.00High
4/30/2020HC WainwrightBoost TargetPositive ➝ Buy$24.00 ➝ $33.00Medium
4/24/2020B. RileyBoost TargetBuy$20.00 ➝ $29.00Low
4/9/2020LADENBURG THALM/SH SHReiterated RatingBuy$28.00Medium
4/8/2020B. RileyReiterated RatingBuy$20.00Low
3/27/2020B. RileyBoost Target$15.00 ➝ $20.00High
3/25/2020Cantor FitzgeraldBoost TargetPositive ➝ Overweight$16.00 ➝ $23.00High
3/25/2020HC WainwrightBoost TargetBuy$17.00 ➝ $24.00High
3/24/2020B. RileyBoost TargetBuy$15.00 ➝ $20.00High
3/24/2020LADENBURG THALM/SH SHBoost TargetBuy$16.00 ➝ $24.00High
3/24/2020OppenheimerBoost Target$13.00 ➝ $19.00Medium
3/17/2020Cantor FitzgeraldUpgradeNeutral ➝ Overweight$6.00 ➝ $16.00High
2/28/2020B. RileyBoost TargetBuy$12.00 ➝ $16.00High
2/27/2020HC WainwrightReiterated RatingBuyHigh
1/22/2020HC WainwrightInitiated CoverageBuy$17.00High
1/21/2020B. RileyReiterated RatingBuy$12.00High
11/27/2019B. RileyInitiated CoverageBuy$12.00High
11/8/2019LADENBURG THALM/SH SHReiterated RatingBuy$27.50Low
10/17/2019Cantor FitzgeraldReiterated RatingNeutralHigh
9/24/2019B. RileySet TargetBuy$35.00High
9/24/2019CitigroupLower TargetBuy$19.00 ➝ $15.00Low
9/10/2019OppenheimerLower TargetOutperform$25.00 ➝ $13.00Low
8/14/2019HC WainwrightBoost TargetBuy ➝ Buy$10.00 ➝ $17.00High
7/1/2019HC WainwrightReiterated RatingBuy ➝ Positive$10.00 ➝ $12.00High
6/13/2019HC WainwrightSet TargetBuy$10.00Medium
5/13/2019OppenheimerBoost Target$1.25 ➝ $25.00High
5/10/2019Chardan CapitalReiterated RatingNeutral$7.00N/A
5/9/2019Cantor FitzgeraldReiterated RatingHoldHigh
5/3/2019HC WainwrightReiterated RatingBuy$40.00Low
3/19/2019Cantor FitzgeraldSet TargetHold$20.00High
3/19/2019HC WainwrightBoost TargetPositive ➝ Buy$40.00 ➝ $42.60High
3/4/2019B. RileyLower TargetBuy ➝ Buy$200.00 ➝ $35.00Medium
2/28/2019HC WainwrightReiterated RatingBuy$120.00High
2/28/2019JPMorgan Chase & Co.DowngradeOverweight ➝ UnderweightHigh
2/28/2019Piper Jaffray CompaniesDowngradeOverweight ➝ UnderweightHigh
1/29/2019Cantor FitzgeraldReiterated RatingHold$40.00Low
1/28/2019HC WainwrightInitiated CoverageBuy$120.00High
1/4/2019LADENBURG THALM/SH SHSet TargetBuy$80.00High
1/3/2019Piper Jaffray CompaniesBoost TargetOverweight ➝ Positive$90.00High
12/18/2018LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$60.00High
12/11/2018CIBCInitiated CoverageOutperform ➝ Outperform$80.00Low
12/10/2018OppenheimerInitiated CoverageOutperform$80.00 ➝ $80.00Medium
12/2/2018Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$38.60High
11/26/2018Piper Jaffray CompaniesUpgradeNeutral ➝ OverweightHigh
11/23/2018Cantor FitzgeraldReiterated RatingNeutralHigh
11/19/2018Cantor FitzgeraldSet TargetHold$40.00Low
10/8/2018B. RileySet TargetBuy$200.00High
9/26/2018Cantor FitzgeraldSet TargetHold$40.00N/A
9/21/2018JPMorgan Chase & Co.UpgradeUnderweight ➝ Overweight$40.00 ➝ $45.00High
4/17/2018Piper Jaffray CompaniesLower TargetNeutral$40.00Medium
3/29/2018B. RileyReiterated RatingBuyHigh
3/19/2018JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightMedium
3/15/2018Cantor FitzgeraldReiterated RatingHold$40.00Medium
3/1/2018Chardan CapitalReiterated RatingHoldHigh
3/1/2018CitigroupUpgradeNeutral ➝ BuyHigh
3/1/2018Piper Jaffray CompaniesBoost TargetNeutral$50.00High
3/1/2018LADENBURG THALM/SH SHReiterated RatingBuy$70.00High
3/1/2018B. RileySet TargetBuy$200.00High
2/21/2018CitigroupBoost TargetNeutral ➝ Neutral$40.00 ➝ $55.00Low
2/20/2018CitigroupReiterated RatingHold$60.00High
1/11/2018B. RileySet TargetBuy$200.00High
1/11/2018LADENBURG THALM/SH SHBoost TargetBuy$50.00Low
1/10/2018S&P Equity ResearchLower Target$36.20 ➝ $27.00High
1/5/2018B. RileySet TargetBuy ➝ Buy$45.00 ➝ $45.00Medium
12/19/2017CitigroupDowngradeBuy ➝ Neutral$20.00High
12/18/2017Cantor FitzgeraldReiterated RatingHold$40.00High
(Data available from 12/7/2017 forward)

News Sentiment Rating

0.41 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 13 very positive mentions
  • 45 positive mentions
  • 10 negative mentions
  • 3 very negative mentions
5/11/2022
  • 12 very positive mentions
  • 49 positive mentions
  • 13 negative mentions
  • 4 very negative mentions
6/10/2022
  • 10 very positive mentions
  • 29 positive mentions
  • 7 negative mentions
  • 3 very negative mentions
7/10/2022
  • 17 very positive mentions
  • 41 positive mentions
  • 14 negative mentions
  • 0 very negative mentions
8/9/2022
  • 12 very positive mentions
  • 34 positive mentions
  • 13 negative mentions
  • 11 very negative mentions
9/8/2022
  • 6 very positive mentions
  • 30 positive mentions
  • 9 negative mentions
  • 2 very negative mentions
10/8/2022
  • 4 very positive mentions
  • 29 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/7/2022
  • 14 very positive mentions
  • 12 positive mentions
  • 6 negative mentions
  • 4 very negative mentions
12/7/2022

Current Sentiment

  • 14 very positive mentions
  • 12 positive mentions
  • 6 negative mentions
  • 4 very negative mentions

Recent Stories by Sentiment

Novavax logo
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Read More

Today's Range

Now: $17.14
Low: $16.36
High: $17.77

50 Day Range

MA: $19.44
Low: $16.30
High: $25.04

52 Week Range

Now: $17.14
Low: $15.53
High: $236.50

Volume

69,752 shs

Average Volume

4,632,220 shs

Market Capitalization

$1.35 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.76

Frequently Asked Questions

What sell-side analysts currently cover shares of Novavax?

The following Wall Street analysts have issued research reports on Novavax in the last twelve months: B. Riley, Bank of America Co., Cantor Fitzgerald, Cowen Inc, Cowen Inc., HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., and StockNews.com.
View the latest analyst ratings for NVAX.

What is the current price target for Novavax?

8 Wall Street analysts have set twelve-month price targets for Novavax in the last year. Their average twelve-month price target is $109.25, suggesting a possible upside of 537.4%. HC Wainwright has the highest price target set, predicting NVAX will reach $207.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $27.00 for Novavax in the next year.
View the latest price targets for NVAX.

What is the current consensus analyst rating for Novavax?

Novavax currently has 2 sell ratings, 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NVAX, but not buy more shares or sell existing shares.
View the latest ratings for NVAX.

What other companies compete with Novavax?

How do I contact Novavax's investor relations team?

Novavax's physical mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company's listed phone number is (240) 268-2000 and its investor relations email address is [email protected] The official website for Novavax is www.novavax.com. Learn More about contacing Novavax investor relations.